Tertiary Prevention of Head and Neck Cancer With a Dietary Intervention

Cancer of Head and Neck Clinical Trial

— DietINT  

Official title:

A Randomized Phase II Study for Tertiary Prevention of Squamocellular Cancer of Head and Neck (SCCHN) With a Dietary Intervention

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02869399
• Other study ID #: INT 18/15
• Status: Completed
• Phase: N/A
• Start date: November 2015
• Est. completion date: February 2023

Study information

• Verified date: April 2022
• Source: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label randomized phase II multicenter trial. An estimated 350 patients deemed to be in complete remission at month 3 after curative treatment are considered for this trial. Two arms of intervention are foreseen: the experimental arm (arm A) based on dietary intervention in addition to standard recommendations and a control arm (arm B) including only standard recommendations. The intervention strategy is based on the AICR/WCRF recommendations for cancer and recurrences prevention and it is focused on decreasing inflammation, glycaemia and insulinaemia while promoting nutrient-rich diet. The reduction in the incidence of tumor recurrence will be analyzed comparing EFS curves between the two arms with the non-parametric Kaplan-Meier method. Secondary analyses will describe the time trend in the prevalence of side effects and quality of life, as assessed by the EORTC QLQ-H&N35 questionnaire. Translational analysis (cytokine, salivary and plasmatic miRNA) will be performed. The trial is coordinated by Istituto Nazionale Tumori, Milan and conducted in 6 European countries.

Description:

Patients deemed to be in complete remission at month 3 (+/- 1 month) after curative treatment will be considered for this trial. At each follow up visit the patients will state all the changes and new symptoms they experienced and they will receive both physical and fiberoptic endoscopic head and neck examination. Locoregional imaging should preferentially be performed within 6 months after treatment end and then will be recommended only on the occurrence of new signs or symptoms. Late adverse events of the treatment will be evaluated at each visit according to Common Toxicity Criteria of Adverse Events (CTCAE version 4.0). Quality of life questionnaire (EORTC QLQ HN35) and VSAQ questionnaire will be administered to patients every other visit. Laboratory tests including a complete blood count, renal, hepatic and thyroid function will be performed once a year. The analysis of blood biomarkers of compliance and efficacy will be conducted at baseline, 3, 6, 12, 18 and 24 months after randomization. The proposed study foresees two arms of intervention: the experimental arm based on dietary intervention in addition to standard recommendations and a control arm which includes only standard recommendations. The intervention strategy will focus on reducing inflammation and reducing glycaemia and insulinaemia while promoting nutrient-rich diet. Patients will be taught how to prepare traditional Mediterranean meals (healthy, satiating, palatable and easy to prepare). Patients in the control arm will not receive specific suggestions concerning diet, but standard healthy lifestyle recommendations will be given. The recommendations, including nutritional consultation if needed by standard practice of care, will be reinforced at each clinical visit and through a leaflet according to primary cancer prevention nutritional guidelines. Patients in the control group are encouraged to follow the WCRF/AICR recommendations but they will not receive any of the recipes or educational materials given to the intervention group.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 94
• Est. completion date: February 2023
• Est. primary completion date: November 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• High-risk effectively cured stage III and IV HNSCC
• Oropharyngeal cancer will be enrolled only if with a smoking history of more than 10 pack/years
• Able to swallow at least a soft pureed diet
• Male or female > 18 years
• Signed written informed consent

Exclusion Criteria:

• Serious or uncontrolled co-existent non-malignant disease, including active and uncontrolled infection
• Non parotid-sparing RT
• Severely malnourished patients (patients with a weight loss greater that 5% in the last month before enrollment and with a BMI < 20)
• Diabetic patients in pharmacological treatment
• Participation in clinical trials with other experimental agents within 30 days of study entry or concomitant treatment with other experimental drug
• Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study
• Other significant disease that in the investigator's opinion would exclude the subject from the trial
• Patients unable to comply with the protocol, in the opinion of the investigator

Related Conditions & MeSH terms

• Cancer of Head and Neck
• Head and Neck Neoplasms

Intervention

Dietary Supplement:
• dietary intervention in addition to standard recommendations
The diet of the intervention group will be based on the AICR/WCRF recommendations for cancer prevention and for the prevention of recurrences (www.dietandcancerreport.org): avoid or limit alcoholic drinks (2 drinks men, 1 drink women) increase consumption of a variety of non-starchy vegetables, fruits (at least 400g per day) and dietary fibers (at least 25g per day) eat mostly food of plant origin eat lean meat, limit intake of red meat and avoid processed meat increase consumption of anti-inflammatory foods, such as fish and whole grain cereals, f.e. brown rice and barley creams avoid high glycaemic and high insulinemic foods, such as refined flours, white breads, and pastries

Locations

Country	Name	City	State
Austria	Medical University of Vienna	Vienna
Germany	Klinik und Poliklinik für Hals-, Nasen-, Ohrenheilkunde	Leipzig
Italy	Fondazione IRCCS Istituto Nazionale Tumori	Milan	Lombardy
Poland	The Greater Poland Cancer Centre	Poznan
Portugal	Grupo de Estudos de Cancro da Cabeça e Pescoço	Lisbon
Slovenia	Institute of Oncology Ljubljana	Ljubljana

Sponsors (1)

Lead Sponsor	Collaborator
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Countries where clinical trial is conducted

Austria,  Germany,  Italy,  Poland,  Portugal,  Slovenia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reduction in the incidence of tumor recurrence and second primaries	Reduction in the incidence of tumor recurrence and second primaries will be assessed. When a clinical or radiological evidence of recurrence exists, all the efforts should be made in order to perform a histological confirmation. It is possible that a certain amount of recurrences will not be cyto/histologically confirmed due to tumor location not making the sampling feasible. It will be accepted a maximum percentage of 10% of such cases, if in presence of at least 2 different concordant radiological imaging.	36 months
Primary	Identification of saliva and plasma miRNAs and evaluation of their change in the 2 arms of treatment	The project involves the monitoring of miRNAs during the dietary intervention to ascertain the effectiveness of the treatment and the relationship with clinical outcome	36 months
Primary	Change in inflammatory cytokine profile during the course of dietary intervention	The change in inflammatory cytokine profile during the course of dietary intervention and the comparison with control arm will be evaluated	36 months
Secondary	Reduction of treatment related side effects	Reduction of treatment related side effects (e.g. xerostomia, fatigue, mucositis), assessed according to CTCAE v 4.0 (physician assessed symptoms) will be evaluated during study course.	36 months
Secondary	EORTC HN35 quality of life scales	The improvement of Quality of Life assessed according to EORTC HN35 questionnaires (patient reported outcome) will be evaluated	36 months
Secondary	Identification of cytokine and growth factors	Identification of cytokines and growth factors in blood and their change during the course of dietary intervention; comparison with control arm; Identification of tumor DNA in saliva and blood	36 months
Secondary	Monitoring of DNA methylation	The monitoring of DNA methylation obtained from salivary rinses in the 2 groups will help to identify biomarkers associated to the outcome of the treatment	36 months